Get the Stockscreener App
11.93
0.08%
0.00898
Amneal Pharmaceuticals Inc stock is traded at $11.93, with a volume of 415.02K.
It is up +0.08% in the last 24 hours and down -14.23% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$11.92
Open:
$11.9
24h Volume:
415.02K
Relative Volume:
0.23
Market Cap:
$3.80B
Revenue:
$3.05B
Net Income/Loss:
$181.32M
P/E Ratio:
31.92
EPS:
0.3737
Net Cash Flow:
$225.64M
1W Performance:
-5.32%
1M Performance:
-14.23%
6M Performance:
+3.56%
1Y Performance:
+59.07%
1-Day Range:
$11.76
$12.04
1-Week Range:
$11.76
$12.64
52-Week Range:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.93 | 3.80B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.66 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.235 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.13 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.38 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
569.33 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | UBS | Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Should value investors buy Amneal Pharmaceuticals (AMRX) stock? - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Amneal Pharmaceuticals, Inc.Class A Common Stock (Nasdaq:AMRX) Stock Quote - The Chronicle-Journal
AMRX Should I Buy - Intellectia AI
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX) - Yahoo Finance
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - Yahoo Finance
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Sahm
Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg - Stock Titan
[144] Amneal Pharmaceuticals, Inc. SEC Filing - Stock Titan
Do options traders know something about Amneal stock we don't? - MSN
Amneal (AMRX) Q3 2025 Earnings Call Transcript - AOL.com
AMRX SEC FilingsAmneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality - Sahm
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BUCHI J KEVIN - Moomoo
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant - Stock Titan
Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director George Jeffrey P. - Moomoo
Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units - Stock Titan
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares - Stock Titan
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX) - Stock Titan
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant - Stock Titan
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant - Stock Titan
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks
Amneal Pharmaceuticals Q1 2026 & M&A announcement Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition - Stock Titan
Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23% - Stock Titan
Amneal (NASDAQ: AMRX) investors back directors, say-on-pay and EY as auditor - Stock Titan
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M - marketscreener.com
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held - Stock Titan
Amneal Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, Vs. FactSet Est of $719.7M - Moomoo
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, Vs. FactSet Est of $0.22 - Moomoo
Number of shareholders of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vishrut Awasthi Joins Amneal Pharmaceuticals to Lead India Strategy and Business Development - hrtoday.in
Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus - Yahoo Finance
Do Options Traders Know Something About Amneal Stock We Don't? - Yahoo Finance
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting Around The New US$17 Price Target - Yahoo Finance
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast - Investing.com
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):